Free for academic non-profit institutions. Other users need a Commercial license
This gene encodes a member of the G protein-coupled receptor family, as well as the EDG family of proteins. This protein functions as a cellular receptor for lysophosphatidic acid and mediates lysophosphatidic acid-evoked calcium mobilization. This receptor couples predominantly to G(q/11) alpha proteins. [provided by RefSeq, Jul 2008]
LPAR3 (Lysophosphatidic Acid Receptor 3) is a Protein Coding gene. Diseases associated with LPAR3 include Ovarian Cancer and Triple-Receptor Negative Breast Cancer. Among its related pathways are RET signaling and Signaling by GPCR. Gene Ontology (GO) annotations related to this gene include G protein-coupled receptor activity and phospholipid binding. An important paralog of this gene is LPAR1.
GeneHancer (GH) Identifier | GH Type | GH Score |
GH Sources | Gene Association Score | Total Score | TSS distance (kb) | Number of Genes Away | Size (kb) | Transcription Factor Binding Sites |
Gene Targets |
---|---|---|---|---|---|---|---|---|---|---|
GH01J084892 | Promoter/Enhancer | 1.9 | EPDnew Ensembl ENCODE CraniofacialAtlas | 610.1 | +0.3 | 305 | 1.8 | PRDM10 ZNF629 ZNF692 ZIC2 PATZ1 CTCF ZNF501 POLR2A EZH2 ZNF600 | LPAR3 HSALNG0004831 ENSG00000271576 ZNHIT6 LOC102724892 SSX2IP | |
GH01J084896 | Enhancer | 0.3 | Ensembl | 600.7 | -0.9 | -895 | 0.2 | SCRT2 EZH2 | HSALNG0004831 LPAR3 piR-59928-008 MCOLN2 | |
GH01J084895 | Enhancer | 0.3 | ENCODE | 600.7 | -1.6 | -1627 | 0.2 | EZH2 | HSALNG0004831 LPAR3 piR-59928-008 MCOLN2 | |
GH01J084894 | Enhancer | 0.3 | ENCODE | 600.7 | -1.5 | -1467 | 0.2 | EZH2 | HSALNG0004831 LPAR3 piR-59928-008 MCOLN2 | |
GH01J084851 | Enhancer | 1.4 | FANTOM5 Ensembl ENCODE dbSUPER | 16.6 | +39.6 | 39605 | 6 | BACH1 JUND PKNOX1 IKZF2 TRIM22 HDAC1 ETV6 YY1 EP300 SCRT2 | LPAR3 BCL10 GNG5 MCOLN2 C1orf52 LOC102724892 SSX2IP |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0001965 | G-protein alpha-subunit binding | IEA | -- |
GO:0004930 | G protein-coupled receptor activity | TAS,IBA | 21873635 |
GO:0005543 | phospholipid binding | IEA | -- |
GO:0008289 | lipid binding | TAS | 10488122 |
GO:0070915 | lysophosphatidic acid receptor activity | IEA | -- |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0005623 | cell | IEA | -- |
GO:0005737 | cytoplasm | IBA | 21873635 |
GO:0005886 | plasma membrane | TAS | -- |
GO:0005887 | integral component of plasma membrane | TAS | 10488122 |
GO:0016020 | membrane | IEA | -- |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | Peptide ligand-binding receptors | ||
2 | Signaling by GPCR | ||
3 | RET signaling | ||
4 | Pathways in cancer | ||
5 | Phospholipase D signaling pathway |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000187 | activation of MAPK activity | IEA | -- |
GO:0007165 | signal transduction | IEA | -- |
GO:0007186 | G protein-coupled receptor signaling pathway | TAS | -- |
GO:0007187 | G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | TAS | 10488122 |
GO:0007189 | adenylate cyclase-activating G protein-coupled receptor signaling pathway | IBA | 21873635 |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
farnesyl diphosphate | Experimental | Pharma | Antagonist, Agonist | 0 | ||
Ki16425 | Pharma | Antagonist | LPA receptor antagonist | 0 | ||
1-Oleoyl lysophosphatidic acid sodium salt | Pharma | Activates LPA receptor, Endogenous agonist of LPA1 and LPA2 | 0 | |||
GRI 977143 | Pharma | LPA2 receptor non-lipid agonist, Selective LPA2 receptor non-lipid agonist | 0 | |||
H2L 5765834 | Pharma | LPA1,3,5 antagonist | 0 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs | |
---|---|---|---|---|---|---|
dioctanoy?àëlglycerol?àë pyrophos?àëphate |
|
Antagonist |
|
|||
LysoPA(0:0/16:0) |
|
|
||||
LysoPA(0:0/18:0) |
|
|
|
|||
LysoPA(0:0/18:1(9Z)) |
|
|
||||
LysoPA(0:0/18:2(9Z,12Z)) |
|
|
|
Compound | Action | Cas Number |
---|---|---|
1-Oleoyl lysophosphatidic acid sodium salt | Endogenous agonist of LPA1 and LPA2 | 325465-93-8 |
GRI 977143 | Selective LPA2 receptor non-lipid agonist | 325850-81-5 |
H2L 5765834 | LPA1,3,5 antagonist | 420841-84-5 |
H2L5186303 | Potent and selective LPA2 receptor antagonist | 139262-76-3 |
TC LPA5 4 | LPA5 receptor antagonist | 1393814-38-4 |
Compound | Action | Cas Number |
---|---|---|
1-Oleoyl lysophosphatidic acid sodium salt | Activates LPA receptor | 325465-93-8 |
GRI 977143 | LPA2 receptor non-lipid agonist | 325850-81-5 |
H2L 5765834 | 420841-84-5 | |
H2L5186303 | 139262-76-3 | |
Ki16198 | LPA antagonist | 355025-13-7 |
Ki16425 | LPA receptor antagonist | 355025-24-0 |
TC LPA5 4 | 1393814-38-4 |
This gene was present in the common ancestor of chordates.
Organism | Taxonomy | Gene | Similarity | Type | Details |
---|---|---|---|---|---|
Chimpanzee (Pan troglodytes) |
Mammalia | LPAR3 30 31 |
|
OneToOne | |
Dog (Canis familiaris) |
Mammalia | LPAR3 30 31 |
|
OneToOne | |
Cow (Bos Taurus) |
Mammalia | LPAR3 30 31 |
|
OneToOne | |
Oppossum (Monodelphis domestica) |
Mammalia | LPAR3 31 |
|
OneToOne | |
Platypus (Ornithorhynchus anatinus) |
Mammalia | LPAR3 31 |
|
OneToOne | |
Mouse (Mus musculus) |
Mammalia | Lpar3 30 17 31 |
|
OneToOne | |
Rat (Rattus norvegicus) |
Mammalia | Lpar3 30 |
|
||
Chicken (Gallus gallus) |
Aves | LPAR3 30 31 |
|
OneToOne | |
Lizard (Anolis carolinensis) |
Reptilia | LPAR3 31 |
|
OneToOne | |
Tropical Clawed Frog (Silurana tropicalis) |
Amphibia | lpar3 30 |
|
||
Zebrafish (Danio rerio) |
Actinopterygii | lpar2a 30 |
|
SNP ID | Clinical significance and condition | Chr 01 pos | Variation | AA Info | Type |
---|---|---|---|---|---|
717261 | Benign: not provided | 84,865,779(-) | A/C | SYNONYMOUS_VARIANT | |
780244 | Benign: not provided | 84,814,046(-) | C/T | MISSENSE_VARIANT | |
789692 | Benign: not provided | 84,814,083(-) | T/C | SYNONYMOUS_VARIANT | |
rs35745543 | - | p.Arg231Gln |
Disorder | Aliases | PubMed IDs |
---|---|---|
ovarian cancer |
|
|
triple-receptor negative breast cancer |
|
|